Ivermectin shows promise as potential COVID-19 therapy.

Summary: An FDA-approved anti-parasitic drug called Ivermectin appears to inhibit and eliminate SARS-CoV-2 in lab-grown cell cultures within 48 hours. Ivermectin shows promise as potential COVID-19 therapy. However, researchers stress the need for further testing and clinical trials in humans to confirm the effectiveness of the drug and appropriate dosage levels.

Source: Monash University

Monash scientists have shown that an anti-parasitic drug already available around the world can kill the virus within 48 hours.

Scientists from the Biomedicine Discovery Institute (BDI) showed that a single dose of the drug, Ivermectin, could stop the SARS-CoV-2 virus growing in cell culture.

This Monash University-led collaborative study was published in Antiviral Research, a peer-reviewed medical journal Antiviral Research.

Whilst shown to be effective in the lab environment, Ivermectin cannot be used in humans for COVID-19 until further testing and clinical trials have been completed to confirm the effectiveness of the drug at levels safe for human dosing. The potential use of Ivermectin to combat COVID-19 remains unproven, and depends on funding to progress the work into the next stages.

Image Credit:  Amanda Scott/Alias/Envato

News This Week

Aging Spreads Through the Bloodstream

Summary: New research reveals that aging isn’t just a local cellular process—it can spread throughout the body via the bloodstream. A redox-sensitive protein called ReHMGB1, secreted by senescent cells, was found to trigger aging features [...]

Nanomaterials in Ophthalmology: A Review

Eye diseases are becoming more common. In 2020, over 250 million people had mild vision problems, and 295 million experienced moderate to severe ocular conditions. In response, researchers are turning to nanotechnology and nanomaterials—tools that are transforming [...]